Author + information
Introduction: Durable polymer drug eluting stent (DEP) has endothelial anti-proliferative properties that can decrease stent restenosis rates. We sought to compare the safety and efficacy of BEP to DEP for treatment of ACS.
Methods: Pub Med and Chochrane database were searched using all RCT's that compared BEP to DEP for the treatment of CAD. We stratified our analysis into short-term (< 12 months) and long-term (> 12 months). Primary endpoint included TLR and probable or definite stent thrombosis (ST). Secondary endpoints included death and AMI. We used fixed or random effect analysis using the Cochrane Handbook of Systematic Reviews.
Results: A total of 12 studies were included in the short-term analysis providing a total of 10,735 patients (5,888 patients in the BEP group and 4,847 in DEP). There was no difference in the TVR between BEP and DEP (39% vs. 38%, p=0.5) and ST (38% vs. 37%, p=0.5). There was no difference in mortality and AMI between the two groups (Table 1). In the long-term analysis, 4 RTC's provided a total of 7,874 patients (4,379 in the BEP group and 3,495 in DEP). There was a trend towards less TVR in the DEP group (7.8% vs. 8.4%, p=1). There was no difference in ST, death and AMI (Table 2).
Conclusions: Our analysis suggested similar outcomes between BEP and DEP. We can conclude that BEP is safe and efficacious for treatment of stable and non-complex coronary lesions when compared to DEP. Further RCT's should be done to determine the clinical application of BEP in STEMI and complex PCI.
Poster Hall, Hall C
Friday, March 17, 2017, 3:45 p.m.-4:30 p.m.
Session Title: Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease
Abstract Category: 3. Acute and Stable Ischemic Heart Disease: Therapy
Presentation Number: 1165-309
- 2017 American College of Cardiology Foundation